You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康方生物-B(09926.HK):包括2項以LBA研究形式發佈在內的6項產品研究的最新資料將在SITC2020上呈列
格隆匯 10-28 06:19

格隆匯 10 月 28日丨康方生物-B(09926.HK)發佈公告,公司將在2020年11月10日至15日線上舉辦的第35屆腫瘤免疫治療學會年會(“SITC 2020”)上公佈6項與公司產品相關的最新研究資料,包括以突破性成果((Late Breaking Abstract)“LBA”)研究形式公佈派安普利單抗(AK105,PD-1)2項臨牀研究進展,以及以海報形式介紹CD47單抗(AK117)、CD73單抗(AK119)、TIGIT單抗(AK127)以及PD-1/CD73(AK123)雙抗的最新研究進展。有關詳情將陸續發佈於公司網站:www.akesobio.com。

其中,以LBA研究形式發佈派安普利單抗(AK105,PD-1)的兩項臨牀研究,標題分別是:《PD-1單抗派安普利在二線或以上已接受化療治療的轉移性鼻咽癌患者中開展的II期臨牀研究》和《PD-1單抗派安普利在復發或難治性經典型霍奇金淋巴瘤患者中開展的II期臨牀研究》。

以海報形式呈列4項最新的研究結果分別是:標題I:《一種用於COVID-19免疫治療的人源化CD73單克隆抗體:AK119》;標題II:《使用PD-1/CD73雙特異性抗體雙重阻斷PD-1免疫檢查點通路和腺苷負反饋信號通路的腫瘤免疫治療》;標題III:《一項評估下一代抗CD47單克隆抗體(AK117)用於治療復發╱難治性的晚期或轉移性實體瘤或淋巴瘤患者的安全性、藥代動力學和抗腫瘤活性的1期臨牀研究》;標題IV:《兩種具有不同結合表位和功能活性的TIGIT抗體》。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account